Table 1 Comparison of clinicopathological characteristics between the two groups of patients studied
PDS group (n = 90) | IDS group (n = 163) | P value | |
|---|---|---|---|
Age (years) | 51 (46, 58) | 52 (47, 60) | 0.333 |
BMI (kg/m2) | 22.90 (20.50, 25.11) | 22.59 (20.96, 24.61) | 0.801 |
FIGO stage | 0.000 | ||
IIIC | 85 (94.4%) | 124 (76.1%) | |
IVA | 1 (1.1%) | 9 (5.5%) | |
IVB | 4 (4.4%) | 30 (18.4%) | |
ECOG PS | 0 (0–1) | 2 (1–2) | 0.000 |
Pathological type | 0.000 | ||
Serous carcinoma | 73 (81.1%) | 131 (80.4%) | |
Mucinous carcinoma | 1 (1.1%) | 2 (1.2%) | |
Clear cell carcinoma | 6 (6.7%) | 3 (1.8%) | |
Endometrioid adenocarcinoma | 1 (1.1%) | 2 (1.2%) | |
Mixed carcinoma a | 7 (7.8%) | 2 (1.2%) | |
Carcinosarcoma | 1 (1.1%) | 0 | |
Unknown type | 1 (1.1%) | 23 (14.1%) | |
Tumor differentiation | 0.591 | ||
G1 | 5 (6.0%) | 7 (4.8%) | |
G2 | 0 | 1 (0.7%) | |
G3 | 78 (94.0%) | 138 (94.5%) | |
Residual disease after surgery | 0.003 | ||
R0 | 35 (38.9%) | 98 (60.1%) | |
R1 | 30 (33.3%) | 42 (25.8%) | |
R2 | 25 (27.8%) | 23 (14.1%) | |
Chemotherapy regimen | 0.330 | ||
Paclitaxel/carboplatin | 89 (98.9%) | 160 (98.2%) | |
Paclitaxel/carboplatin+ bevacizumab | 0 | 1 (0.6%) | |
Other regimens | 1 (1.1%) | 2 (1.2%) | |
Postoperative chemotherapy cycles | 7 (6, 8) | 6 (5, 8) | 0.051 |
Interval from surgery to the first cycle of postoperative chemotherapy (days) | 8 (6, 10) | 7 (7, 10) | 0.283 |
CA125 before treatment (U/ml) | 801.20 (359.63, 1815.25) | 1226.00 (595.40, 2424.00) | 0.007 |